Why Pfizer Inc Is A Buy? Acquirer’s Multiple Stock Screener Analysis

Johnny HopkinsStock ScreenerLeave a Comment

As part of our ongoing series here at The Acquirer’s Multiple, each week we focus on one of the stocks from our Stock Screeners, and why it’s a ‘buy’ based on key fundamentals.

One of the cheapest stocks in our Stock Screeners is:

Pfizer Inc (PFE)

Pfizer is one of the world’s largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

A quick look at the share price history (below) over the past twelve months shows that the price is down 46.22%. Here’s why the company is undervalued.

PFE Chart

PFE data by YCharts

Key Stats

Market Cap: $155.99 Billion

Enterprise Value: $175.68 Billion

Operating Earnings

Operating Earnings: $10.54 Billion

Acquirer’s Multiple

Acquirer’s Multiple: 16.70

Free Cash Flow (TTM)

Free Cash Flow: $8.18 Billion

FCF/EV Yield %:

FCF/EV Yield: 5.24

Shareholder Yield %:

Shareholder Yield: 5.90

Other Indicators

Piotroski F Score: 5.00

Altman Z-Score (TTM): 2.523

ROA (5 Year Avge%): 5

For all the latest news and podcasts, join our free newsletter here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.